Milionis Charalampos, Ilias Ioannis, Venaki Evaggelia, Koukkou Eftychia
Department of Endocrinology, Diabetes and Metabolism, General Hospital "Elena Venizelou", Athens, Greece.
Int J Risk Saf Med. 2023;34(1):21-28. doi: 10.3233/JRS-200087.
Gender dysphoria is characterised by a sense of distress because of discordance between the self-perception of gender identity and the assigned sex. Hormonal treatment of transgender males uses testosterone to induce and preserve masculinisation.
The study investigated the safety of testosterone therapy in transgender males.
The present study used a retrospective file review of transgender male subjects who were treated with testosterone (initially transdermal testosterone gel and subsequently parenteral testosterone undecanoate) for at least 18 months and had subsequently achieved a serum testosterone level within the normal range of cisgender male counterparts. Changes in somatometric data and blood biomarkers were investigated.
The mean testosterone serum levels after approximately 18 months of treatment were about 545 ng/dL (SD ± 94 ng/dL). There was a statistically significant rise in body mass index (𝜒d = +1.23 kg/m2) with a reduction in blood glucose (𝜒d = -5.33 mg/dL) as well as statistically significant increases in aspartate transaminase (𝜒d = +4.3 U/L), haemoglobin (𝜒d = +1.72 g/dL), and haematocrit (𝜒d = +4.76%). In contrast, there were no significant changes in the lipidaemic profile of the subjects.
Treatment with testosterone is routinely used for the promotion of virilising physical changes in transgender males. However, the likelihood of adverse effects of continuous treatment is still unclear. This study contributed to the notion that achieving testosterone levels within the target range is a prerequisite for the safety of the gender-affirming treatment.
性别焦虑症的特征是由于性别认同的自我认知与指定性别之间的不一致而产生的困扰感。对跨性别男性的激素治疗使用睾酮来诱导和维持男性化特征。
本研究调查了睾酮治疗对跨性别男性的安全性。
本研究对接受睾酮治疗（最初使用经皮睾酮凝胶，随后使用十一酸睾酮注射剂）至少18个月且血清睾酮水平随后达到顺性别男性对应范围内的跨性别男性受试者进行了回顾性档案审查。研究了身体测量数据和血液生物标志物的变化。
治疗约18个月后的平均血清睾酮水平约为545 ng/dL（标准差±94 ng/dL）。体重指数有统计学显著升高（χd = +1.23 kg/m²），血糖降低（χd = -5.33 mg/dL），同时天冬氨酸转氨酶（χd = +4.3 U/L）、血红蛋白（χd = +1.72 g/dL）和血细胞比容（χd = +4.76%）有统计学显著升高。相比之下，受试者的血脂谱无显著变化。
睾酮治疗常用于促进跨性别男性的男性化身体变化。然而，持续治疗产生不良反应的可能性仍不清楚。本研究支持了这样一种观点，即达到目标范围内的睾酮水平是性别确认治疗安全的先决条件。
